# Antares Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/antares-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.antaresrx.com/
- Total disclosed funding: $30M
- Latest round: Series A (May 1, 2025)
- Investors on record: 10

## About

Antares Therapeutics, Inc. is a Boston-based biotechnology company focused on developing precision medicines for oncology and serious diseases through innovative therapeutic approaches.Antares Therapeutics, Inc. specializes in creating targeted therapies for challenging medical conditions, primarily in oncology. The company was founded to advance the treatment of serious illnesses through cutting-edge scientific research. It is headquartered in Boston, US. The CEO is Adam Friedman, who has a background in founding similar biotech ventures. In May 2025, the company raised USD 30 mn in Series A funding, co-led by investors including Omega Funds and Atlas Venture, with a total fundraising amount of USD 30 mn to date and a current valuation of USD 257.55 mn.AntaresRX specializes in the development of precision medicines aimed at transforming patient care, particularly in oncology. The company's core offerings include next-generation small molecule therapeutics targeting previously undruggable proteins, specifically transcription factors and mutant EGFR inhibitors for non-small cell lung cancer. These therapies address significant unmet medical needs by leveraging advanced technologies in medicinal chemistry, target biology, and predictive sciences. AntaresRX collaborates with established pharmaceutical partners such as AstraZeneca and Pierre Fabre Laboratories to ensure broad access to its products in key markets, including North America and Europe.AntaresRX generates revenue through collaborations and partnerships with pharmaceutical companies, which fund the development and commercialization of its therapeutic products. This includes joint development agreements and licensing deals, with the company receiving upfront payments, milestone payments based on developmental success, and royalties on future sales. Such transactions are instrumental for the advancement of its product candidates, including the selective PARP1 inhibitor MOMA-989 and the EGFR inhibitors PFL-721 and PFL-241, which are designed as potential best-in-class treatments.Antares Therapeutics plans to utilize the recent USD 30 mn funding raised in May 2025 to expand its operations and enhance research and development efforts. The company aims to introduce new therapeutics in its pipeline while targeting expansion into additional markets in North America and Europe. This strategic funding will support the ongoing development of its innovative therapies, positioned to meet the needs of patients with serious medical conditions.

## Funding rounds

- Series A, May 1, 2025, $30M — Abingworth, Atlas Venture, Lightspeed Venture Partners, Invus [DUP], Willett Advisors, Omega Funds, BVF Partners, Cormorant Asset Management, Vida Ventures, Tenmile

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A
- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Series A
- Invus [DUP] — Series A
- Willett Advisors — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A
- BVF Partners (https://capitalatlas.ai/funds/bvf-partners) — Series A
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A
- Tenmile (https://capitalatlas.ai/funds/tenmile) — Series A